Study Start-Up Challenges: Hard Realities, Effective Strategies

By IQVIA, Novartis

According to the Tufts Center for the Study of Drug Development, the average time between protocol approval and the first patient visit increased 45% between 2015 and 2021. Preparing a site for start-up is complex; and since the COVID-19 pandemic, several factors have increased the time it takes to get to the first patient’s first visit. This slowdown in start-ups causes delays in product launches and ROI. At the same time, speed-to-market is more important than ever, as exclusivity periods have been cut in half over the past two decades. Are there any effective strategies to reverse this trend of ballooning study start-up timelines?

IQVIA Technologies asked Raphaëlle Gilg of Novartis Pharmaceuticals and colleagues Kerry Randall, Rodrigo Guimarães, and Rosemary Shirey to share their best practices in the webinar titled Practical Approaches to Faster Study Start-ups: Making Progress in the Face of Industry Headwinds. These industry leaders shared pragmatic, actionable steps that pharmaceutical and biotech companies of all sizes can implement to accelerate study start-ups and get innovative drugs to patients more quickly and efficiently.